Tumor markers and colorectal cancer: utility in management

J Surg Oncol. 2003 Dec;84(4):239-48. doi: 10.1002/jso.10325.

Abstract

Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Although genetic testing can screen for rare hereditary CRC syndromes, there is no ideal means of screening for sporadic forms of CRC. This review will focus on markers that are currently used in the management of sporadic CRC and their limitations, as well as possible future clinical applications.

Publication types

  • Review

MeSH terms

  • Adenomatous Polyposis Coli / diagnosis
  • Adenomatous Polyposis Coli / genetics
  • Antibodies, Monoclonal / immunology
  • Biomarkers, Tumor / blood*
  • Cancer Vaccines / therapeutic use
  • Carcinoembryonic Antigen / blood
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / diagnostic imaging
  • Colorectal Neoplasms / therapy
  • Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis
  • Genetic Markers*
  • Humans
  • Occult Blood
  • Ornithine Decarboxylase / blood
  • Prognosis
  • Radioimmunodetection

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • Cancer Vaccines
  • Carcinoembryonic Antigen
  • Genetic Markers
  • Ornithine Decarboxylase